secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001104659-24-084357
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q2 2024: net loss $34.7M on investment fair-value hit; royalty revenue $67.2M
--------------------------------------------------------------------------------

- GSK royalty revenue $67.2M vs $65.7M YoY; net product sales $21.7M (+38% YoY).
- Net loss of $34.7M ($0.55 basic loss) due to $90.7M unfavorable change in equity investments.
- License revenue $14.5M including $8M milestone from XACDURO approval in China.
- Completed $100M share repurchase program; repurchased 0.4M shares in Q2 for $5.3M.
- XACDURO approved in China; named preferred agent in 2024 IDSA guidance; XERAVA recommended by SIS guidelines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924084357/0001104659-24-084357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924084357/tm2420507d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-084357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer